Copyright
©The Author(s) 2015.
World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 235-242
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.235
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.235
Table 1 Differences in Kaplan-Meier estimated median survival between individual drugs groups
Drug name | Number taking the drug out of 164 patients | Median survival estimate for those taking the drug (d) | Median survival for those not taking the drug (d) | P value (log rank test) |
ACEI/ARB | 41 | 539 | 611 | 0.652 |
CCB | 26 | 815 | 528 | 0.061 |
Aspirin | 55 | 504 | 546 | 0.846 |
Statins | 39 | 504 | 577 | 0.368 |
Table 2 Univariate and multivariate cox regression comparing individual drug groups with those not taking the drug
Drug name | Number taking the drug out of 164 patients | Univariate analysis | Multivariate analysis | ||
HR (95%CI) | P-value | HR (95%CI) | P-value | ||
ACEI/ARB | 41 | 1.094 (0.741-1.614) | 0.653 | 1.129 (0.617-2.065) | 0.693 |
CCB | 26 | 0.635 (0.393-1.025) | 0.063 | 0.475 (0.250-0.902) | 0.023 |
Aspirin | 55 | 1.036 (0.726-1.479) | 0.846 | 1.041 (0.651-1.667) | 0.865 |
Statins | 39 | 1.200 (0.806-1.787) | 0.369 | 1.055 (0.614-1.814) | 0.845 |
Table 3 Kaplan-Meier survival estimates and multivariate cox regression comparing patients taking a combination of medications with patients on one or neither drug
Drug combination | Number of people on | Kaplan-Meier estimated median survival | Multivariate cox regression | |||
combination out of 164 | For those on the drug combination | For those not on drug combination | P-value (log rank) | HR (95%CI) | P-value | |
CCB + aspirin | 15 | 1414 | 528 | 0.012 | 0.300 (0.122-0.735) | 0.008 |
CCB + statin | 12 | 544 | 539 | 0.284 | 0.413 (0.155-1.101) | 0.077 |
CCB + ACEI/ARB | 12 | 485 | 541 | 0.450 | 0.512 (0.194-1.348) | 0.175 |
Aspirin + statin | 27 | 504 | 546 | 0.697 | 0.969 (0.509-1.844) | 0.924 |
Aspirin + ACEI/ARB | 22 | 485 | 569 | 0.923 | 0.948 (0.438-2.054) | 0.893 |
Statin + ACEI/ARB | 21 | 368 | 577 | 0.426 | 1.126 (0.533-2.379) | 0.756 |
Table 4 Comparison of differences in prognostic indicators between drug groups
Characteristics | No CCB/aspirin, n (%) | CCB and aspirin, n (%) | Aspirin without CCB, n (%) | CCB without Aspirin, n (%) | P value |
n = 98 | n = 15 | n = 40 | n = 11 | ||
Sex | |||||
Male | 56 (57.1) | 5 (33.3) | 25 (62.5) | 8 (72.7) | 0.169 |
Age (yr) | |||||
< 60 | 39 (39.8) | 5 (33.3) | 8 (20.0) | 3 (27.3) | 0.157 |
≥ 60 | 59 (60.2) | 10 (66.7) | 32 (80.0) | 8 (72.7) | |
Blood pressure status | |||||
Hypertensive | 27 (27.6) | 13 (86.7) | 22 (55.0) | 11 (100.0) | 0.000 |
Non-hypertensive | 71 (72.4) | 2 (13.3) | 18 (45.0) | 0 (0.0) | |
BMI | |||||
< 18.5 | 2 (2.0) | 0 (0) | 1 (2.5) | 0 (0.0) | 0.307 |
18.5-25 | 52 (53.1) | 5 (33.3) | 24 (60.0) | 3 (27.3) | |
> 25 | 41 (41.8) | 9 (60.0) | 14 (35.0) | 8 (72.7) | |
Adjuvant chemotherapy | |||||
Received post-op | 69 (70.4) | 9 (60.0) | 23 (57.5) | 9 (81.8) | 0.333 |
Not received | 24 (24.5) | 5 (33.3) | 13 (32.5) | 1 (9.1) | |
CA19-9 | |||||
< 47 | 27 (27.6) | 3 (20.0) | 9 (22.5) | 1 (9.1) | 0.437 |
47-1000 | 51 (52.0) | 7 (46.7) | 20 (50.0) | 7 (63.6) | |
> 1000 | 8 (8.2) | 3 (20.0) | 6 (15.0) | 3 (27.3) | |
ASA grade | |||||
1-2 | 81 (82.7) | 12 (80.0) | 22 (55.0) | 8 (72.7) | 0.008 |
3-4 | 17 (17.3) | 3 (20.0) | 18 (45.0) | 3 (27.3) | |
Resection value | |||||
R0 | 14 (14.3) | 6 (40.0) | 9 (22.5) | 5 (45.5) | 0.020 |
R1 | 83 (84.7) | 9 (60.0) | 31 (77.5) | 6 (54.5) | |
T status | |||||
T1-2 | 3 (3.1) | 2 (13.3) | 1 (2.5) | 0 (0.0) | 0.199 |
T3-4 | 95 (96.9) | 13 (86.7) | 39 (97.5) | 11 (100.0) | |
N status | |||||
N0 | 7 (7.1) | 3 (20.0) | 5 (12.5) | 0 (0.0) | 0.242 |
N1 | 90 (91.8) | 12 (80) | 35 (87.5) | 11 (100.0) |
Table 5 Kaplan-Meier survival estimates and multivariate cox regression comparing patients taking a combination of calcium channel blockers + aspirin with patients on one or neither drug
Drug group | Number of people | Estimated median | P-value (log rank) | Multivariate cox regression | |
in group | survival (d) | compared to control | HR (95%CI) | P-value | |
Control (no CCB/aspirin) | 98 | 601 | - | 1 | - |
CCB + aspirin | 15 | 1414 | 0.029 | 0.332 (0.126-0.870) | 0.025 |
Aspirin without CCB | 40 | 392 | 0.032 | 1.658 (0.968-2.840) | 0.066 |
CCB without Aspirin | 11 | 343 | 0.563 | 1.039 (0.416-2.595) | 0.935 |
- Citation: Tingle SJ, Moir JA, White SA. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol 2015; 6(4): 235-242
- URL: https://www.wjgnet.com/2150-5330/full/v6/i4/235.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v6.i4.235